Rezolute, Inc. develops therapies aimed at improving the quality of life for individuals suffering from rare diseases, specifically focusing on hyperinsulinism (HI). The company is engaged in the development of transformative treatments to alleviate severe hypoglycemia associated with HI. Rezolute operates Phase 3 clinical programs for congenital and tumor-related HI, and it also runs an Expanded Access Program to provide access to its therapies.
- Website
- www.rezolutebio.com
- Issuer profile
- All listings